Ece Özoğul, Anna Montaner, Melina Pol, Gerard Frigola, Olga Balagué, Charlotte Syrykh, Pablo Bousquets-Muñoz, Romina Royo, Juliette Fontaine, Alexandra Traverse-Glehen, Marco M Bühler, Luca Giudici, Marco Roncador, Thorsten Zenz, Sylvain Carras, Severine Valmary-Degano, Laurence de Leval, Jan Bosch-Schips, Fina Climent, Julia Salmeron-Villalobos, Melika Bashiri, Silvia Ruiz-Gaspà, Dolors Costa, Sílvia Beà, Itziar Salaverria, Eva Giné, Leticia Quintanilla-Martinez, Pierre Brousset, Mark Raffeld, Elaine S Jaffe, Xose S Puente, Cristina López, Ferran Nadeu, Elias Campo
{"title":"与套细胞淋巴瘤相比,CCND1重排的大B细胞淋巴瘤具有不同的免疫球蛋白基因断点和基因组特征。","authors":"Ece Özoğul, Anna Montaner, Melina Pol, Gerard Frigola, Olga Balagué, Charlotte Syrykh, Pablo Bousquets-Muñoz, Romina Royo, Juliette Fontaine, Alexandra Traverse-Glehen, Marco M Bühler, Luca Giudici, Marco Roncador, Thorsten Zenz, Sylvain Carras, Severine Valmary-Degano, Laurence de Leval, Jan Bosch-Schips, Fina Climent, Julia Salmeron-Villalobos, Melika Bashiri, Silvia Ruiz-Gaspà, Dolors Costa, Sílvia Beà, Itziar Salaverria, Eva Giné, Leticia Quintanilla-Martinez, Pierre Brousset, Mark Raffeld, Elaine S Jaffe, Xose S Puente, Cristina López, Ferran Nadeu, Elias Campo","doi":"10.1038/s41408-024-01146-z","DOIUrl":null,"url":null,"abstract":"<p><p>Mantle cell lymphoma (MCL) is genetically characterized by the IG::CCND1 translocation mediated by an aberrant V(D)J rearrangement. CCND1 translocations and overexpression have been identified in occasional aggressive B-cell lymphomas with unusual features for MCL. The mechanism generating CCND1 rearrangements in these tumors and their genomic profile are not known. We have reconstructed the IG::CCND1 translocations and the genomic profile of 13 SOX11-negative aggressive B-cell lymphomas using whole genome/exome and target sequencing. The mechanism behind the translocation was an aberrant V(D)J rearrangement in three tumors and by an anomalous IGH class-switch recombination (CSR) or somatic hypermutation (SHM) mechanism in ten. The tumors with a V(D)J-mediated translocation were two blastoid MCL and one high-grade B-cell lymphoma. None of them had a mutational profile suggestive of DLBCL. The ten tumors with CSR/SHM-mediated IGH::CCND1 were mainly large B-cell lymphomas, with mutated genes commonly seen in DLBCL and BCL6 rearrangements in 6. Two cases, which transformed from marginal zone lymphomas, carried mutations in KLF2, TNFAIP3 and KMT2D. These findings expand the spectrum of tumors carrying CCND1 rearrangement that may occur as a secondary event in DLBCL mediated by aberrant CSR/SHM and associated with a mutational profile different from that of MCL.</p>","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"14 1","pages":"166"},"PeriodicalIF":12.9000,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11420347/pdf/","citationCount":"0","resultStr":"{\"title\":\"Large B-cell lymphomas with CCND1 rearrangement have different immunoglobulin gene breakpoints and genomic profile than mantle cell lymphoma.\",\"authors\":\"Ece Özoğul, Anna Montaner, Melina Pol, Gerard Frigola, Olga Balagué, Charlotte Syrykh, Pablo Bousquets-Muñoz, Romina Royo, Juliette Fontaine, Alexandra Traverse-Glehen, Marco M Bühler, Luca Giudici, Marco Roncador, Thorsten Zenz, Sylvain Carras, Severine Valmary-Degano, Laurence de Leval, Jan Bosch-Schips, Fina Climent, Julia Salmeron-Villalobos, Melika Bashiri, Silvia Ruiz-Gaspà, Dolors Costa, Sílvia Beà, Itziar Salaverria, Eva Giné, Leticia Quintanilla-Martinez, Pierre Brousset, Mark Raffeld, Elaine S Jaffe, Xose S Puente, Cristina López, Ferran Nadeu, Elias Campo\",\"doi\":\"10.1038/s41408-024-01146-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Mantle cell lymphoma (MCL) is genetically characterized by the IG::CCND1 translocation mediated by an aberrant V(D)J rearrangement. CCND1 translocations and overexpression have been identified in occasional aggressive B-cell lymphomas with unusual features for MCL. The mechanism generating CCND1 rearrangements in these tumors and their genomic profile are not known. We have reconstructed the IG::CCND1 translocations and the genomic profile of 13 SOX11-negative aggressive B-cell lymphomas using whole genome/exome and target sequencing. The mechanism behind the translocation was an aberrant V(D)J rearrangement in three tumors and by an anomalous IGH class-switch recombination (CSR) or somatic hypermutation (SHM) mechanism in ten. The tumors with a V(D)J-mediated translocation were two blastoid MCL and one high-grade B-cell lymphoma. None of them had a mutational profile suggestive of DLBCL. The ten tumors with CSR/SHM-mediated IGH::CCND1 were mainly large B-cell lymphomas, with mutated genes commonly seen in DLBCL and BCL6 rearrangements in 6. Two cases, which transformed from marginal zone lymphomas, carried mutations in KLF2, TNFAIP3 and KMT2D. These findings expand the spectrum of tumors carrying CCND1 rearrangement that may occur as a secondary event in DLBCL mediated by aberrant CSR/SHM and associated with a mutational profile different from that of MCL.</p>\",\"PeriodicalId\":8989,\"journal\":{\"name\":\"Blood Cancer Journal\",\"volume\":\"14 1\",\"pages\":\"166\"},\"PeriodicalIF\":12.9000,\"publicationDate\":\"2024-09-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11420347/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood Cancer Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41408-024-01146-z\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Cancer Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41408-024-01146-z","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Large B-cell lymphomas with CCND1 rearrangement have different immunoglobulin gene breakpoints and genomic profile than mantle cell lymphoma.
Mantle cell lymphoma (MCL) is genetically characterized by the IG::CCND1 translocation mediated by an aberrant V(D)J rearrangement. CCND1 translocations and overexpression have been identified in occasional aggressive B-cell lymphomas with unusual features for MCL. The mechanism generating CCND1 rearrangements in these tumors and their genomic profile are not known. We have reconstructed the IG::CCND1 translocations and the genomic profile of 13 SOX11-negative aggressive B-cell lymphomas using whole genome/exome and target sequencing. The mechanism behind the translocation was an aberrant V(D)J rearrangement in three tumors and by an anomalous IGH class-switch recombination (CSR) or somatic hypermutation (SHM) mechanism in ten. The tumors with a V(D)J-mediated translocation were two blastoid MCL and one high-grade B-cell lymphoma. None of them had a mutational profile suggestive of DLBCL. The ten tumors with CSR/SHM-mediated IGH::CCND1 were mainly large B-cell lymphomas, with mutated genes commonly seen in DLBCL and BCL6 rearrangements in 6. Two cases, which transformed from marginal zone lymphomas, carried mutations in KLF2, TNFAIP3 and KMT2D. These findings expand the spectrum of tumors carrying CCND1 rearrangement that may occur as a secondary event in DLBCL mediated by aberrant CSR/SHM and associated with a mutational profile different from that of MCL.
期刊介绍:
Blood Cancer Journal is dedicated to publishing high-quality articles related to hematologic malignancies and related disorders. The journal welcomes submissions of original research, reviews, guidelines, and letters that are deemed to have a significant impact in the field. While the journal covers a wide range of topics, it particularly focuses on areas such as:
Preclinical studies of new compounds, especially those that provide mechanistic insights
Clinical trials and observations
Reviews related to new drugs and current management of hematologic malignancies
Novel observations related to new mutations, molecular pathways, and tumor genomics
Blood Cancer Journal offers a forum for expedited publication of novel observations regarding new mutations or altered pathways.